RT Journal Article
SR Electronic
T1 Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1458
OP 1461
DO 10.3899/jrheum.180792
VO 46
IS 11
A1 Iain B. McInnes
A1 Lluís Puig
A1 Alice B. Gottlieb
A1 Christopher T. Ritchlin
A1 Michael Song
A1 Yin You
A1 Shelly Kafka
A1 G. James Morgan
A1 Proton Rahman
A1 Arthur Kavanaugh
YR 2019
UL http://www.jrheum.org/content/46/11/1458.abstract
AB Objective. Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among patients with psoriatic arthritis (PsA) who are naive to anti–tumor necrosis factor agents.Methods. In PSUMMIT 1 and 2, patients with PsA were randomized to placebo or ustekinumab 45 mg or 90 mg. Enthesitis was assessed at weeks 0 and 24 (Maastricht Ankylosing Spondylitis Enthesitis Score). Assessments included Health Assessment Questionnaire–Disability Index (HAQ-DI), Medical Outcomes Study Short Form-36 (SF-36) physical component summary/mental component summary (PCS/MCS), and American College of Rheumatology 20 (ACR20).Results. At Week 24, 21 had worsened enthesitis, 158 had improved enthesitis, and 412 had unchanged enthesitis. Improved enthesitis was associated with improvements in HAQ-DI and SF-36 MCS. Results were similar for ACR20 responders and nonresponders.Conclusion. Improvement in enthesitis at Week 24 was associated with improvements in physical function/HRQOL regardless of ACR20 response.